La lamotrigine, \u00e9galement connue sous le nom de Lamictal, est un m\u00e9dicament anti-\u00e9pileptique qui a \u00e9t\u00e9 approuv\u00e9 par la FDA<\/a> for treatment of epilepsy and bipolar disorder. Lamotrigine is used alone or with other medicines to treat seizures in patients two years and older. It may also be used as maintenance treatment in patients with bipolar disorder to help delay the occurrence of mood episodes such as depression, mania, or hypomania. Stopping lamotrigine without first talking to a prescriber can lead to uncontrolled seizures, or new or worsening mental health problems. Lamotrigine has been approved and on the market for 24 years, and is available under the brand name Lamictal and as generics.<\/p>\n Lamictal was first sold in the United States in 1994 and is manufactured by GlaxoSmithKline. It is a sodium channel blocker that helps by suppressing the excitatory neurotransmitters in the central nervous system.\u00a0 Lamictal is available both as an oral tablet and in a chewable form and is metabolized by the liver.\u00a0 Between 2005 and 2015, there were more than 900,000,000 prescriptions for the drug in the United States.\u00a0\u00a0 Lamictal has been one of GlaxoSmithKline\u2019s best-selling drugs of all time and sales between March 2007 and March 2008 exceeded $2 billion.<\/p>\n <\/p>\n En plus d'aider les patients souffrant de troubles de l'humeur, Lamictal \u00e9tait \u00e9galement approuv\u00e9 pour une utilisation<\/a> comme m\u00e9dicament anti\u00e9pileptique.<\/p>\n Un article \u00e9crit en 2008<\/a> by Nasser et al. reviewed evidence from Lamictal trials that were unpublished, and it concludes that lamotrigine has “very limited, if any, efficacy in the treatment of acute bipolar depression”. A Article de 2008 de Calabrese et al.<\/a> ont examin\u00e9 une grande partie des m\u00eames donn\u00e9es et ont constat\u00e9 que dans cinq \u00e9tudes contr\u00f4l\u00e9es par placebo, la lamotrigine ne diff\u00e9rait pas significativement du placebo dans le traitement de la d\u00e9pression bipolaire.<\/p>\n <\/p>\n Une r\u00e9action du syst\u00e8me immunitaire tr\u00e8s grave et potentiellement mortelle a \u00e9t\u00e9 identifi\u00e9e comme un effet secondaire r\u00e9sultant de l'utilisation de Lamictal. Cette r\u00e9action du syst\u00e8me immunitaire est appel\u00e9e HLH (qui signifie lymphohistiocytose h\u00e9mophagocytaire) qui am\u00e8ne le syst\u00e8me immunitaire \u00e0 endommager les tissus et les organes du corps. Cela peut provoquer une inflammation grave dans tout le corps et entra\u00eener une hospitalisation et la mort, surtout si la r\u00e9action n'est pas diagnostiqu\u00e9e et trait\u00e9e rapidement. La HLH se pr\u00e9sente g\u00e9n\u00e9ralement sous la forme d'une fi\u00e8vre persistante, g\u00e9n\u00e9ralement sup\u00e9rieure \u00e0 101 \u00b0 F, et peut entra\u00eener de graves probl\u00e8mes de cellules sanguines et d'organes dans tout le corps, tels que le foie, les reins, le cerveau et les poumons.<\/p>\n <\/p>\n Selon la Food and Drug Administration, un diagnostic de HLH peut \u00eatre \u00e9tabli si un patient pr\u00e9sente au moins cinq des huit signes ou sympt\u00f4mes suivants\u00a0:<\/p>\n Les patients ou leurs soignants doivent contacter imm\u00e9diatement leur professionnel de la sant\u00e9 s'ils ressentent un sympt\u00f4me de HLH pendant qu'ils prennent la lamotrigine. La LHH peut survenir quelques jours \u00e0 quelques semaines apr\u00e8s le d\u00e9but du traitement. Un examen physique et des tests sanguins de laboratoire sp\u00e9cifiques et d'autres \u00e9valuations sont utilis\u00e9s pour diagnostiquer la LHH. Les signes et sympt\u00f4mes de la LHH comprennent, mais sans s'y limiter\u00a0:<\/p>\n <\/p>\n <\/p>\n Le 25 avril 2018, le La FDA a \u00e9mis un avertissement<\/a> that Lamictal can cause this rare, but very serious reaction.\u00a0Because of the association with HLH, the FDA required the manufacturer of Lamictal to add a new warning about the risk of HLH to the prescribing information in the lamotrigine drug labels. \u00a0The FDA also issued an alert to healthcare professionals stating they should be aware that prompt recognition and early treatment is important for improving HLH outcomes and decreasing mortality. Diagnosis is often complicated because early signs and symptoms such as fever and rash are not specific. HLH may also be confused with other serious immune-related adverse reactions such as Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS).<\/p>\n In the 24 years since lamotrigine\u2019s 1994 approval, the FDA identified many cases worldwide of confirmed or suspected HLH associated with the medicine in children and adults. This number includes only reports submitted to FDA and found in the medical literature, so there are likely additional cases about which the FDA is unaware. The FDA determined that \u201cthere was reasonable evidence that lamotrigine was the cause of HLH\u201d in these cases based on the timing of events and the order in which they occurred. The patients in these cases required hospitalization and received drug and other medical treatments, with one patient dying.<\/p>\n <\/p>\n Lamictal a bless\u00e9 des milliers de personnes qui n'avaient aucune id\u00e9e que la drogue \u00e9tait dangereuse. Si vous ou un \u00eatre cher avez re\u00e7u un diagnostic de HLH alors que vous \u00e9tiez sur Lamictal, contactez Napoli Shkolnik PLLC et parlez \u00e0 un professionnel exp\u00e9riment\u00e9. avocat contentieux pharmaceutique<\/a> \u00e0 New York. Nous ne facturons pas de frais juridiques initiaux dans les cas de n\u00e9gligence.<\/p>","protected":false},"excerpt":{"rendered":" WE ARE NO LONGER ACCEPTING LAMICTAL CASES Background Lamotrigine, also known as Lamictal, is an anti-seizure medication that was approved by the FDA for treatment of epilepsy and bipolar disorder….<\/p>","protected":false},"featured_media":0,"menu_order":137,"template":"","practiceareas_category":[743],"class_list":["post-5934","practiceareas","type-practiceareas","status-publish","hentry","practiceareas_category-pharmaceutical-litigation"],"acf":[],"_links":{"self":[{"href":"https:\/\/napolilaw.lemonadestand.org\/fr\/wp-json\/wp\/v2\/practiceareas\/5934","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/napolilaw.lemonadestand.org\/fr\/wp-json\/wp\/v2\/practiceareas"}],"about":[{"href":"https:\/\/napolilaw.lemonadestand.org\/fr\/wp-json\/wp\/v2\/types\/practiceareas"}],"version-history":[{"count":0,"href":"https:\/\/napolilaw.lemonadestand.org\/fr\/wp-json\/wp\/v2\/practiceareas\/5934\/revisions"}],"wp:attachment":[{"href":"https:\/\/napolilaw.lemonadestand.org\/fr\/wp-json\/wp\/v2\/media?parent=5934"}],"wp:term":[{"taxonomy":"practiceareas_category","embeddable":true,"href":"https:\/\/napolilaw.lemonadestand.org\/fr\/wp-json\/wp\/v2\/practiceareas_category?post=5934"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}Lamictal comme m\u00e9dicament anti\u00e9pileptique<\/h3>\n
Lamictal et HLH<\/h3>\n
Informations sur HLH<\/h2>\n
\n
\n
Faits sur la lamotrigine (Lamictal)<\/h2>\n
\n
\n
Action de la FDA pour la s\u00e9curit\u00e9<\/h3>\n
Parlez \u00e0 un avocat<\/h3>\n